Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by Chicago Partners Investment Group LLC

Chicago Partners Investment Group LLC increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating) by 8.5% during the first quarter, Holdings Channel reports. The fund owned 409 shares of the medical research company’s stock after acquiring an additional 32 shares during the quarter. Chicago Partners Investment Group LLC’s holdings in Thermo Fisher Scientific were worth $222,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Advanced Research Investment Solutions LLC boosted its holdings in shares of Thermo Fisher Scientific by 213.3% in the 1st quarter. Advanced Research Investment Solutions LLC now owns 47 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 32 shares during the last quarter. Mystic Asset Management Inc. acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $29,000. Lloyd Advisory Services LLC. boosted its holdings in shares of Thermo Fisher Scientific by 294.1% in the 1st quarter. Lloyd Advisory Services LLC. now owns 67 shares of the medical research company’s stock valued at $40,000 after purchasing an additional 50 shares during the last quarter. Tyler Stone Wealth Management acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $47,000. Finally, Lansing Street Advisors acquired a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at $47,000. Institutional investors and hedge funds own 86.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on TMO shares. Morgan Stanley lifted their price target on shares of Thermo Fisher Scientific from $670.00 to $678.00 and gave the company an “overweight” rating in a report on Friday, July 29th. SVB Leerink lifted their target price on shares of Thermo Fisher Scientific from $630.00 to $650.00 and gave the company an “outperform” rating in a report on Friday, July 29th. Barclays reduced their target price on shares of Thermo Fisher Scientific from $685.00 to $595.00 and set an “overweight” rating on the stock in a report on Monday. Finally, Credit Suisse Group started coverage on shares of Thermo Fisher Scientific in a report on Wednesday, August 24th. They set a “neutral” rating and a $675.00 target price on the stock. One analyst has rated the stock with a sell rating, three have given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $655.64.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 12,300 shares of the business’s stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $603.48, for a total transaction of $7,422,804.00. Following the completion of the transaction, the chief financial officer now directly owns 43,944 shares of the company’s stock, valued at approximately $26,519,325.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, SVP Michael A. Boxer sold 7,283 shares of the company’s stock in a transaction that occurred on Monday, August 8th. The shares were sold at an average price of $590.80, for a total value of $4,302,796.40. Following the completion of the sale, the senior vice president now directly owns 12,398 shares of the company’s stock, valued at approximately $7,324,738.40. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Stephen Williamson sold 12,300 shares of the company’s stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $603.48, for a total transaction of $7,422,804.00. Following the completion of the sale, the chief financial officer now directly owns 43,944 shares of the company’s stock, valued at $26,519,325.12. The disclosure for this sale can be found here. Insiders sold 55,397 shares of company stock valued at $33,012,754 in the last ninety days. Company insiders own 0.43% of the company’s stock.

Thermo Fisher Scientific Price Performance

TMO opened at $551.98 on Friday. The company has a 50-day moving average of $568.28 and a 200-day moving average of $558.69. The company has a market capitalization of $216.26 billion, a P/E ratio of 29.38, a PEG ratio of 1.74 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 1-year low of $497.83 and a 1-year high of $672.34. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.13 and a current ratio of 1.65.

Thermo Fisher Scientific (NYSE:TMOGet Rating) last announced its quarterly earnings data on Thursday, July 28th. The medical research company reported $5.51 earnings per share for the quarter, beating analysts’ consensus estimates of $4.92 by $0.59. Thermo Fisher Scientific had a net margin of 17.37% and a return on equity of 24.36%. The business had revenue of $10.97 billion during the quarter, compared to the consensus estimate of $9.95 billion. During the same quarter in the prior year, the firm earned $5.60 EPS. The company’s revenue for the quarter was up 18.3% compared to the same quarter last year. Equities analysts expect that Thermo Fisher Scientific Inc. will post 22.92 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 14th. Shareholders of record on Thursday, September 15th will be paid a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a yield of 0.22%. The ex-dividend date is Wednesday, September 14th. Thermo Fisher Scientific’s payout ratio is 6.39%.

Thermo Fisher Scientific Company Profile

(Get Rating)

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Recommended Stories

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.